Rhumbline Advisers raised its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 40.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 183,809 shares of the medical technology company’s stock after purchasing an additional 52,630 shares during the period. Rhumbline Advisers owned approximately 0.28% of Hill-Rom worth $16,276,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. IMS Capital Management bought a new stake in Hill-Rom in the 3rd quarter valued at about $71,000. We Are One Seven LLC bought a new stake in Hill-Rom in the 4th quarter valued at about $93,000. Nkcfo LLC bought a new stake in Hill-Rom in the 4th quarter valued at about $162,000. Quantbot Technologies LP boosted its holdings in Hill-Rom by 270.2% in the 3rd quarter. Quantbot Technologies LP now owns 2,051 shares of the medical technology company’s stock valued at $193,000 after purchasing an additional 1,497 shares during the period. Finally, First Light Asset Management LLC bought a new stake in Hill-Rom in the 3rd quarter valued at about $202,000. 86.96% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Hill-Rom from a “hold” rating to a “sell” rating in a report on Monday, February 4th. ValuEngine raised shares of Hill-Rom from a “hold” rating to a “buy” rating in a report on Saturday, January 19th. Raymond James upped their price target on shares of Hill-Rom from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, November 5th. Finally, UBS Group assumed coverage on shares of Hill-Rom in a report on Tuesday, November 27th. They set a “buy” rating and a $115.00 price target for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $102.67.
Shares of Hill-Rom stock opened at $102.91 on Tuesday. Hill-Rom Holdings, Inc. has a 1-year low of $79.36 and a 1-year high of $105.78. The company has a quick ratio of 1.25, a current ratio of 1.70 and a debt-to-equity ratio of 1.17. The company has a market cap of $6.84 billion, a PE ratio of 21.67, a PEG ratio of 1.45 and a beta of 0.95.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, January 25th. The medical technology company reported $1.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.98 by $0.04. The company had revenue of $683.50 million during the quarter, compared to the consensus estimate of $676.39 million. Hill-Rom had a net margin of 7.21% and a return on equity of 21.23%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 EPS. On average, research analysts forecast that Hill-Rom Holdings, Inc. will post 5.06 earnings per share for the current year.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: Backdoor Roth IRA
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.